Andere Sprachen Arvinas, Inc.

Aktien

A2N6VP

US04335A1051

ARVN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 22.05.2024			% 5 Tage	% 1. Jan.
35,95 ^USD	+3,75 %		+11,20 %	-12,66 %

16.05.	Sektor-Update: Aktien des Gesundheitswesens am Donnerstag vorbörslich stabil	MT
16.05.	Sektor Update: Gesundheitswesen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Steady Premarket Thursday	16.05.
Sector Update: Health Care	16.05.
Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity	16.05.
Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity	16.05.
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)	16.05.
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib	16.05.
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress	09.05.
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress	09.05.
Arvinas Shares Up After Q1 Net Loss Narrows	07.05.
Earnings Flash (ARVN) ARVINAS Reports Q1 Revenue $25.3M	07.05.
Arvinas : Corporate Presentation – May 2024	07.05.
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update	07.05.
Arvinas, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Arvinas to Present at Upcoming Investor Conferences	02.05.
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer	24.04.
Arvinas, Inc. Appoints Randy Teel as Chief Business Officer	24.04.
Arvinas : 2024 Proxy Statement	17.04.
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	12.04.
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	12.04.
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024	11.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Arvinas, Inc.

Aktien

A2N6VP

US04335A1051

ARVN

Andere Sprachen

Filter